Tamoxifen reduces serum insulin-like growth factor I (IGF-I)
- PMID: 1421427
- DOI: 10.1007/BF01833337
Tamoxifen reduces serum insulin-like growth factor I (IGF-I)
Abstract
Antiestrogens are widely used in the management of hormonally responsive breast cancer in both adjuvant and palliative settings, and are currently being evaluated as chemopreventive agents. The classical mechanism of action of these drugs involves inhibition of estrogen-stimulated neoplastic cell proliferation by blockade of estrogen receptors present on breast cancer cells. This paper reviews recent clinical and laboratory data that suggest that the commonly used antiestrogen tamoxifen also acts to reduce serum IGF-I levels. Estrogens appear to play a permissive role in growth hormone (GH) release by the pituitary gland and GH is known to stimulate IGF-I expression by hepatocytes. It is therefore possible that blockade of estrogen receptors in the hypothalamic-pituitary axis by tamoxifen interferes with GH release, leading to reduced hepatic IGF-I expression. In view of results suggesting that IGF-I is a more potent mitogen than estradiol for breast cancer cells and data demonstrating a positive correlation between estrogen receptor level and IGF-I receptor level of breast cancer cells, the IGF-I lowering effect of tamoxifen may contribute to the cytostatic activity of the drug. The interrelationships between steroid hormone physiology and IGF-I physiology may have relevance to a variety of commonly used treatments for hormonally responsive cancers.
Similar articles
-
Effect of tamoxifen on serum insulinlike growth factor I levels in stage I breast cancer patients.J Natl Cancer Inst. 1990 Nov 7;82(21):1693-7. doi: 10.1093/jnci/82.21.1693. J Natl Cancer Inst. 1990. PMID: 2231756 Clinical Trial.
-
Effect of tamoxifen on GH and IGF-1 serum level in stage I-II breast cancer patients.Anticancer Res. 2001 Jan-Feb;21(1B):585-8. Anticancer Res. 2001. PMID: 11299809
-
Antiestrogens prevent the stimulatory effects of L-triiodothyronine on cell proliferation.Endocrinology. 1992 Mar;130(3):1145-52. doi: 10.1210/endo.130.3.1537281. Endocrinology. 1992. PMID: 1537281
-
Potential impact on breast cancer risk of circulating insulin-like growth factor I modifications induced by oral HRT in menopause.Gynecol Endocrinol. 1995 Mar;9(1):67-74. doi: 10.3109/09513599509160194. Gynecol Endocrinol. 1995. PMID: 7793303 Review.
-
The GH-IGF-I axis and breast cancer.Trends Endocrinol Metab. 2003 Jan;14(1):28-34. doi: 10.1016/s1043-2760(02)00003-6. Trends Endocrinol Metab. 2003. PMID: 12475609 Review.
Cited by
-
Mammographic density: a potential monitoring biomarker for adjuvant and preventative breast cancer endocrine therapies.Oncotarget. 2017 Jan 17;8(3):5578-5591. doi: 10.18632/oncotarget.13484. Oncotarget. 2017. PMID: 27894075 Free PMC article. Review.
-
Effect of two-4-hydroxyandrostenedione doses on serum insulin-like growth factor I levels in advanced breast cancer.Breast Cancer Res Treat. 1994;30(2):127-32. doi: 10.1007/BF00666055. Breast Cancer Res Treat. 1994. PMID: 7949210 Clinical Trial.
-
Expression of receptors for epidermal growth factor and insulin-like growth factor I by ZR-75-1 human breast cancer cell variants is inversely related: the effect of steroid hormones on insulin-like growth factor I receptor expression.Br J Cancer. 1996 Feb;73(4):477-81. doi: 10.1038/bjc.1996.84. Br J Cancer. 1996. PMID: 8595162 Free PMC article.
-
Fourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancer.Br J Pharmacol. 1993 Oct;110(2):507-17. doi: 10.1111/j.1476-5381.1993.tb13840.x. Br J Pharmacol. 1993. PMID: 8242225 Free PMC article. Review.
-
Associations of insulin-like growth factor and insulin-like growth factor binding protein-3 with mortality in women with breast cancer.Int J Cancer. 2013 Mar 1;132(5):1191-200. doi: 10.1002/ijc.27753. Epub 2012 Sep 1. Int J Cancer. 2013. PMID: 22847383 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources